Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR BNO 1055 + tamoxifen is a combination of a standardized extract of Cimicifuga racemosa (black cohosh), known as CR BNO 1055, and the selective estrogen receptor modulator (SERM) tamoxifen. - **CR BNO 1055** is an ethanolic extract of black cohosh rhizome used primarily for menopausal symptoms such as hot flashes and night sweats. Its mechanism appears to involve modulation of serotonin receptors (notably 5-HT1A and 5-HT7), dopaminergic activity via D2 receptors, possible μ-opioid receptor affinity, and SERM-like effects in certain tissues without uterotrophic activity[1][6][7]. - **Tamoxifen** is a well-established SERM that acts as an estrogen receptor antagonist in breast tissue but can have agonist effects in other tissues. It is widely used for hormone receptor-positive breast cancer treatment and prevention. The rationale for combining these agents may be to manage menopausal symptoms or mitigate side effects associated with endocrine therapy in women with or at risk for breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CR BNO 1055 + tamoxifen.